Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial

    loading  Checking for direct PDF access through Ovid


Pancreatic enzyme therapy does not normalize dietary fat absorption in patients with cystic fibrosis (CF) and pancreatic insufficiency (PI). Efficacy of LYM-X-SORBTM (LXS), an easily absorbable lipid matrix that enhances fat absorption was evaluated in a 12-month randomized, double-blinded, placebo-controlled trial with plasma fatty acids (FA), and coefficient of fat absorption (CFA) outcomes. 110 subjects (age 10.4 ± 3.0 y) were randomized. Total FA increased with LXS at 3 and 12 months (+1.58; +1.14 mmol/L) and not with placebo (P = 0.046). With LXS, linoleic acid (LA) increased at 3 and 12 months (+298; +175 nmol/mL, P  ≤ 0.046), with a 6% increase in CFA (P  < 0.01). LA increase was significant in LXS vs. placebo (445 vs. 42 nmol/mL, P  = 0.038). Increased FA and LA predicted increased BMI Z scores. In summary, LXS treatment improved dietary fat absorption compared to placebo as indicated by plasma FA and LA and was associated with better growth status.

Related Topics

    loading  Loading Related Articles

Join Ovid Insights!

Benefits of Ovid Insights Include:

  • Consolidated email digests of the latest research in your favorite topics
  • A personalized dashboard of your topics all on one page 
  • Tools to bookmark and share articles of interest
  • Ability to customize and save your own searches

Register with Ovid Insights »